Treatment of Post-Herpetic Neuralgia When Single-Drug Therapy Has Failed to Provide Adequate Relief

Post-herpetic neuralgia (PHN) presents a persistent neuropathic pain challenge that is not always resolved by a single agent. When monotherapy fails to achieve adequate analgesia — or side-effects prevent reaching an effective dose — a structured multimodal approach becomes the appropriate next step.

This protocol applies to patients with PHN in whom monotherapy, including treatment with TCAs or gabapentinoids, has proved ineffective or has not been tolerated at an effective dose. A different therapeutic strategy is required.

Treatment approach: The regimen is built around combination therapy using at least two agents that work through different mechanisms of action. The specific pairing and full clinical details are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

When monotherapy proves ineffective and fails to provide adequate analgesia, or side-effects fail to achieve an effective dose with TCAs or gabapentinoids, combination therapy may be an appropriate option for a patient with PHN.
The combination of gabapentin and morphine in one study proved more effective in controlling neuropathic pain in PHN than using these medications alone.
The combination of pregabalin and lidocaine 5% has been shown to be efficient in PHN sufferers in whom other single-drug treatment options have failed to provide sufficient pain relief.

View source ↗